Pulmonary Levodopa Particles for Parkinson's Disease Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional L-Dopa therapy for Parkinson's disease is ineffective in later stages due to short plasma half-life, leading to fluctuating symptoms and frequent dosing, which is inconvenient and often results in non-compliance and hospitalization for overdose management.
Innovation Solution
Administering particles with greater than 90% levodopa content to the pulmonary system, specifically to the deep lung, using a method that includes non-reducing sugars like trehalose and phospholipids, and optionally a salt like sodium chloride, to enhance stability and delivery efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If conventional oral L-Dopa therapy is used, then the drug can be administered easily, but the plasma half-life is very short (1-3 hours) leading to fluctuating symptoms and frequent dosing requirements
Solution Approach 1:
The invention segments the L-Dopa delivery system into pulmonary particles that can be inhaled directly into the lungs, bypassing the gastrointestinal tract. This segmentation allows the drug to enter the bloodstream through the pulmonary capillaries, achieving faster and more sustained plasma levels without requiring frequent oral dosing.
Solution Approach 2:
The invention uses the pulmonary system as an intermediary route of administration. By delivering L-Dopa through inhalation into the lung tissue and pulmonary circulation, the drug achieves a mediator effect that bypasses the limitations of oral absorption and first-pass metabolism, resulting in improved plasma half-life and reduced dosing frequency.
2Reliability
If frequent dosing schedules are implemented to maintain plasma levels, then symptom control may be improved, but patient convenience decreases and compliance deteriorates
Solution Approach 1:
The pulmonary particle formulation provides continuous release of L-Dopa into the bloodstream, maintaining stable plasma levels over an extended period. This continuous action eliminates the need for frequent dosing while ensuring reliable symptom control, thereby improving patient compliance and convenience.
3Duration of action of moving object
If high doses of L-Dopa are administered to overcome short half-life, then plasma levels can be maintained, but the risk of overdose and dyskinesis increases
Solution Approach 1:
The invention changes the delivery parameters by using pulmonary inhalation instead of oral administration. This parameter change results in more controlled and predictable absorption kinetics, allowing for lower doses to achieve the same therapeutic effect with reduced risk of overdose and dyskinesis, while maintaining extended plasma half-life.
4Speed
If oral L-Dopa is administered during symptom crises, then rapid increase in brain dopamine activity is needed, but the 30-45 minute onset period causes unnecessary suffering
Solution Approach 1:
The invention substitutes the mechanical process of oral dissolution and gastrointestinal absorption with direct pulmonary delivery. The inhaled particles are rapidly absorbed through the extensive pulmonary capillary network, achieving brain dopamine activity increase within minutes rather than 30-45 minutes, while ensuring reliable symptom relief effectiveness.
Data Source
AI summary
In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.